Literature DB >> 2497979

Induction of an endogenous tumor necrosis factor in mice by murine recombinant interferon-gamma combined with a lipid A subunit analog (GLA-60) of low toxicity.

I Saiki1, H Maeda, T Sakurai, J Murata, J Iida, M Kiso, A Hasegawa, I Azuma.   

Abstract

We have investigated the endogenous production of a serum cytotoxic factor when recombinant interferon-gamma (rIFN-gamma) is combined with synthetic lipid A subunit analogs of low toxicity (GLA compounds). The cytotoxic activity of the serum was measured by the crystal violet staining method with L929 cells as a target. Intravenous administration of rIFN-gamma followed by intravenous administration of lipopolysaccharide induced the endogenous production of a cytotoxic factor in the serum. The priming effect of rIFN-gamma appeared immediately and persisted for approximately 20 h after the injection. Administration of lipopolysaccharide as a trigger enhanced the production of the cytotoxic factor in the serum maximally 2 h after the injection. The cytotoxic activity in the serum was completely inhibited by anti-(mouse tumor necrosis factor) (TNF) antibody. A synthetic lipid A subunit analog (GLA-60), which is much less toxic in its endotoxin activities than lipopolysaccharide or synthetic lipid A (compound 506), induced the endogenous production of serum TNF in rIFN-gamma-primed mice. GLA-60 entrapped within liposomes induced the production of serum TNF in rIFN-gamma-primed mice more effectively than GLA-60 solubilized in phosphate-buffered saline. Intravenous or intranasal administrations of rIFN-gamma followed by intranasal administration of GLA-60 produced TNF in the lung washing fluid but not in the serum, indicating that TNF production can be induced locally rather than systemically by the alteration of the administration route of the primer and trigger. These results indicate that GLA-60, a lipid A subunit analog of low toxicity, is a beneficial triggering agent in the production of endogenous TNF, as well as having other immunopharmacological properties, and may provide a basis for cancer (metastases) treatment as a result of its ability to induce endogenous TNF.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2497979     DOI: 10.1007/bf00199284

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  41 in total

1.  Synergistic anti-proliferative activity of interleukin 1 and tumor necrosis factor.

Authors:  V Ruggiero; C Baglioni
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

2.  Anti-tumour therapy by induction of endogenous tumour necrosis factor.

Authors:  M Kato; R Kakehi; G I Soma; T Gatanaga; D Mizuno
Journal:  Lancet       Date:  1985-08-03       Impact factor: 79.321

3.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

4.  Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.

Authors:  T Espevik; I S Figari; G E Ranges; M A Palladino
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

5.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

Authors:  J L Urban; H M Shepard; J L Rothstein; B J Sugarman; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

6.  Effect of human monocyte killing of tumour cells of antibody raised against an extracellular monocyte cytotoxin.

Authors:  N Matthews
Journal:  Immunology       Date:  1983-02       Impact factor: 7.397

7.  Generation and characterization of a lipopolysaccharide-induced and serum-derived cytotoxic factor for tumor cells.

Authors:  D N Männel; M S Meltzer; S E Mergenhagen
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

8.  Enhancement of resistance to infections by endotoxin-induced serum factor from Mycobacterium bovis BCG-infected mice.

Authors:  M A Parant; F J Parant; L A Chedid
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

9.  The human LT system. XI. Identification of LT and "TNF-like" forms from stimulated natural killers, specific and nonspecific cytotoxic human T cells in vitro.

Authors:  R S Yamamoto; C F Ware; G A Granger
Journal:  J Immunol       Date:  1986-09-15       Impact factor: 5.422

10.  Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon.

Authors:  G Trinchieri; M Kobayashi; M Rosen; R Loudon; M Murphy; B Perussia
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more
  5 in total

1.  Antimetastatic effect of endogenous tumor necrosis factor induced by the treatment of recombinant interferon gamma followed by an analogue (GLA-60) to synthetic lipid A subunit.

Authors:  I Saiki; H Maeda; J Murata; N Yamamoto; M Kiso; A Hasegawa; I Azuma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models.

Authors:  E Kumazawa; A Tohgo; T Soga; T Kusama; Y Osada
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Improvement of macrophage dysfunction by administration of anti-transforming growth factor-beta antibody in EL4-bearing hosts.

Authors:  H Maeda; S Tsuru; A Shiraishi
Journal:  Jpn J Cancer Res       Date:  1994-11

4.  DT-5461, a new synthetic lipid A analogue, inhibits lung and liver metastasis of tumor in mice.

Authors:  K Sato; I Saiki; Y C Yoo; Y Igarashi; M Kiso; A Hasegawa; I Azuma
Journal:  Jpn J Cancer Res       Date:  1992-10

5.  Induction of tumor necrosis factor in mice by recombinant human macrophage colony-stimulating factor.

Authors:  T Sakurai; S Suzu; M Yamada; N Yanai; T Kawashima; K Hatake; F Takaku; K Motoyoshi
Journal:  Jpn J Cancer Res       Date:  1994-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.